Cardiac function is determined by the dynamic equilibrium of various cell types and the extracellular matrix that composes the heart. Cardiovascular diseases (CVDs), 
| INTRODUC TI ON
Cell death (CD) is critical to maintaining tissue homeostasis and basic biological functions, and its changes have significant implications in disease pathology. Since CD was first described in the1960s, many types of CD have been defined based on differences in morphological and biochemical characteristics. 1 In the past, CD in the cardiovascular system was considered passive and negative. In addition, CD was previously believed to occur due to the loss of function of living cells and subsequent inflammation. This situation has changed with the description of apoptosis in the 1970s. In general, apoptosis is essential to maintain cardiovascular homeostasis. Both reduced and increased apoptosis can result in pathology. 2 The maintenance of the normal structure and function of the cardiovascular system requires a balance between cell formation and death in the tissues and organs of the cardiovascular system (including cardiomyocytes [CMs] , endothelial cells [ECs] , vascular smooth muscle cells [VSMCs] and cardiac fibroblasts [CFs] ). Excessive CD (including pyroptosis) often leads to dysfunction of tissues and organs. 3 Pyroptosis was first identified in the macrophage in 1992, which presented rapid lysis after infection with Shigella flexneri, 4 and the name was coined in 2001. 5 Pyroptosis plays a pivotal role in the pathogenesis of various CVDs and involves ECs, 6 VSMCs 7 and so on. This process occurs in patients suffering from myocardial infarction (MI), 8, 9 hypertension 10,11 and cardiomyopathy, 12 as well as in animal models of ischaemia-reperfusion injury (IRI), 13 atherosclerosis (As), 6 heart failure (HF) 14 and cardiomyopathy. 15, 16 Pyroptosis is a highly regulated cell death process, and inhibition of this process by pharmacological or genetic intervention is cardioprotective under many conditions. 6, 17 Therefore, this process is a potential target for therapeutic intervention to prevent CVDs. In summary, the discovery of pyroptosis has broadened our understanding of CD in CVDs, and targeting this manner of CD provides new avenues for the treatment and management of CVDs. This review provides a current overview of the evidence and functional role of pyroptosis in
CVDs and discusses the molecular pathways involved in the cardiovascular system. tosis in 1972 to describe the disappearance of cells during embryonic development, the morphological pattern of normal adult cell renewal in healthy adult tissues and cell atrophy death after hormone cessation. Apoptosis is a highly regulatable pathway of PCD. 25 Cysteine protease causes cell matrix lysis, nucleus condensation, DNA cleavage and plasma membrane shrinkage, simultaneously extensive plasma membrane bubbles and numerous apoptosis body are generating.
Neither the cytoplasmic contents will be released outside the cell nor any inflammatory reactions triggered during this process. 26 Autophagy is a conserved intracellular degradation pathway that delivers cytosolic contents to lysosomes via double-membrane autophagosomes to degrade longevity proteins, misfolded proteins and excess or defective organelles. 27 Autophagy in most tissues occurs at the basal level and contributes to the renewal of cytoplasmic components. It plays a role in the development, differentiation and tissue remodelling of various organisms. Autophagy is highly induced in pathological conditions and increased by more than 10 times. Cell necrosis is a passive process of acute CD mainly caused by physical and chemical stimulation, often leading to cell swelling, rupture and uncontrolled release of inflammatory contents. 28 Necroptosis is also a pro-inflammatory CD that occurs under caspase-8 inhibition, allowing the activation of the receptor interacting protein kinase 1-receptor interacting protein kinase 3-mixed lineage kinase domain-like axis. 29 Necroptosis is a regulated form of cell death morphologically characterized by cell and organelle swelling, which ultimately culminates in the loss of plasma membrane integrity and mild chromatin condensation but intact nuclei. 30 Pyroptosis is characterized by rapid plasma membrane disruption, followed by release of cellular contents and pro-inflammatory mediators, including IL-1β and IL-18. 31 Unlike most cytokines, IL-1β
and IL-18 are not secreted by the classical endoplasmic reticulumGolgi pathway but are produced as biologically inactive precursor proteins that are cleaved prior to their secretion as bioactive cytokines. 32 IL-1β is synthesized initially as an inactive precursor molecule (pro-IL-1β p35), which must be cleaved by caspase-1 at amino acid position 116 to produce the actively mature IL-1β (p17). the production of interferon-γ and potentiation of cytolytic activity of natural killer cells and T cells (Th17 cells) and may polarize T cells towards Th1 or Th2 profiles in combination with other cytokines. 34 Pyroptosis mainly includes the canonical pathway of caspase-1 dependence and the non-canonical pathway involving caspase-4,5
(human) and caspase-11 (mouse; Figure 1 ). 35 The cells activate their respective inflammasomes, including NLRP3, absent in melanoma 2 (AIM2), or pyrin through the action of pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs) under the stimulation of hyperlipidaemia, HG and inflammation ( Figure 2 ). After the activation of NLRP3, the N-terminal pyrin domain (PYD) of NLRP3 serves as a scaffold to nucleate apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC), which contains a pyrin domain and a caspase activation and recruitment domain (CARD).
Through its pyrin domain, ASC interacts with sensor molecules, and the CARD domain interacts with pro-caspase-1 (p45) and initiates pro-caspase-1 self-cleavage to form a caspase-1 mature body (p10/p20 tetramer). On the one hand, activated caspase-1 recognizes inactive IL-β and IL-18 precursors and converts them into mature inflammatory cytokines. On the other hand, caspase-1
cleaves GSDMD (a member of the Gasdermin protein family consisting of more than 500 amino acids) and oligomerizes 31 kDa amino-terminal products (GSDMD-N) that mediate the formation of membrane pores. The formation of membrane pores promotes the release of inflammatory factors, cell swelling and, finally, pyroptosis. 36, 37 In the non-canonical pathway (caspase-1-independent pathway), F I G U R E 1 Caspase-1-dependent and independent pyroptotic pathway. In caspase-1-dependent pyroptosis pathway, the cells activate their respective inflammasome (including NLRP3, AIM2 or pyrin) through the action of pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), under the stimulation of hyperlipidaemia, hyperglycaemia and inflammation; NLRP3 oligomerizes and recruits ASC and pro-caspase-1, triggering the activation of caspase-1 and the maturation and secretion of proinflammatory cytokines such as IL-1β and IL-18. GSDMD-N formed by inflammatory caspase cleavage then mediates cell membrane pore formation, and promotes inflammatory factor release, cell swelling and pyroptosis. In caspase-1-independent pyroptosis pathway, Gramnegative bacterial cell wall component LPS activates caspase-4/5/11 pathway to mediate cell pyroptosis Nek7 is an essential component of NLRP3 inflammasome activation. Nek7 has been primarily characterized as a factor regulating microtubule network nucleation and spindle formation during mitosis. 41 In the pyroptosis system, Nek7 could be involved in the formation or provision of a common signal that functions upstream of NLRP3. Nek7 as a regulator of microtubule dynamics could facilitate the interaction between NLRP3 and ASC. Morphologically, pyroptosis appears to be a combination of apoptosis and necrosis and involves the loss of plasma membrane integrity and the release of cellular contents. The GSDMD-N domain mediates the formation of small pores with a diameter of about 10-14 nm in the plasma membrane. Of note, these pores are wide enough for the passage of mature IL-1β (4.5 nm) and caspase-1 (7.5 nm). The cells appear to be osmotically swollen and form spherical vesicles around the nucleus. 43 As the cell expands, the nucleus becomes spherical and condensed, and the DNA fragments. As with apoptosis, the pyroptosis TUNEL assay is also positive. Pyroptosis can also be observed by electron microscopy, lactate dehydrogenase (LDH) release and Hoechst 33342/PI double-staining, etc. Cathepsin inhibition abolishes the interaction between NLRP3 and ASC. Furthermore, CTSB has been described in some settings to directly cleave caspase-1 and caspase-11, mediating both canonical and non-canonical pyroptosis. 55, 56 In the third mode, the NLRP3 agonist (eg, HG, hyperlipidaemia) triggers the production of reactive oxygen species (ROS) and further activates the NLRP3 inflammasome.
58
In addition to the above three modes, the adipokine visfatin (a major injurious adipokine during obesity) is also thought to activate the NLRP3 inflammasome to induce pyroptosis. 59 This mode plays an important role in vascular endothelial oxidative stress injury and participates in various obesity-related diseases, such as diabetes 60 and coronary atherosclerosis. 61 Moreover, potassium release is associated with all NLRP3 activators, and low-potassium medium alone is sufficient to trigger NLRP3 activation. 62 However, whether NLRP3 directly senses this low level of potassium remains to be determined.
Among the three mechanisms, the third one is the most closely related to CVDs. The source of ROS is currently not clearly understood.
In general, the main source of intracellular ROS is mitochondria and mitochondria produce ROS including electron transport chains and non-electron transfer chains. 63 The electron transport on the mitochondrial electron transport chain is carried out in a step-by-step manner, which dramatically increases the chance of ROS production.
Complexes I and III on the electron transport chain are considered the primary sites for ROS production. In addition to the site of ROS generation in the electron transport chain, other ROS production sites, such as cytochrome b reductase and monoamine oxidase, exist in the mitochondria. 64 In addition to the ROS generation system, the body also has a ROS clearance system, which includes ROS scavenging enzymes and antioxidant systems. Under physiological conditions, ROS generation and clearance in the body are in equilibrium.
However, when mitochondrial dysfunction occurs, the expression of complexes on the electron transport chain becomes abnormal. This phenomenon increases the probability of electrons escaping from the electron transport chain, causing abnormal ROS production and imbalanced clearance, resulting in excessive ROS generation that causes oxidative stress damage, further aggravating mitochondrial damage and triggering diseases such as, As, HF and so on.
65,66
| AIM2 inflammasome
AIM2 is an innate immune sensor, which contains two major domains: an N-terminal PYD domain and a C-terminal HIN domain.
It can detect damaged and aberrant DNA within the cytosolic compartment. AIM2 is also a key sensor of pathogens that detects foreign DNA accumulating in the cytosol during the life cycle of intracellular pathogens, including viruses, bacteria and parasites. 67 A recent study has found that AIM2 can detect DNA damage directly within the nucleus. 68 AIM2 activation initiates the assembly of the inflammasome, an innate immune complex that activates inflammatory caspases and triggers pyroptosis. 69 Microbial DNA and host DNA induce caspase-1 activation dependent of ASC but independent of NLRP3, TLRs or interferon signalling pathway. 
| Pyrin inflammasome
Pyrin is a large protein (86 kDa 
| PYROP TOS IS IN C ARD I OVA SCUL AR DISE A SE
Adult CMs are post-mitotic cells with insufficient ability to respond to injury. In general, acute injury often leads to various types of CD, whereas chronic stress mainly leads to hypertrophy and myocardial remodelling. Increasing evidence shows a slow turnover in normal myocardium maintained by stem cells. However, under pathological conditions, death beyond the mitosis of CMs leads to heart dysfunction. 2 Pyroptosis is involved in various CVDs (eg, As, MI and cardiomyopathy) by mediating CD and inflammation. Intervention in pyroptosis-related molecules (eg, caspase-1, NLRP3, GSDMD and ASC) can significantly affect CVD progression and outcomes. Therefore, an in-depth understanding of the role and molecular mechanisms of pyroptosis in CVDs can provide new potential targets for treatment.
| Atherosclerosis
As is a chronic progressive disease characterized by abnormal lipid deposition in the aorta, obstructing blood flow and subsequent plaque rupture that causes coronary heart disease (CHD) and stroke.
As remains the primary cause of morbidity and mortality worldwide. 74 Both innate and adaptive immune responses, which mainly involve monocytes, macrophages, neutrophils, T lymphocytes and B lymphocytes, are essential for the initiation and progression of As. 75 In summary, As may be considered a chronic inflammatory disease caused by interactions among modified lipoproteins, monocyte-derived macrophages, T cells and ECs. CD can be observed in As and plays a vital role in the development and progression of As lesions.
Pyroptosis is involved in the formation and progression of As by promoting the release of inflammatory factors and is closely related to the stability of the plaque. 44 The most well known of many inflammasomes is NLRP3, which is thought to bridge the gap between lipid metabolism and inflammation because of cholesterol crystals, and oxidized low-density lipoprotein (oxLDL) can activate the NLRP3 inflammasome to induce pyroptosis. Despite this, there are also reports that the NLRP3 inflammasome does not play an important role in As because the absence of NLRP3 does not affect the progression of As lesions and plaque stability in high-fat diet (HFD)-fed ApoE −/− mice (a commonly used animal model of As). 
| Vascular endothelial cell pyroptosis in atherosclerosis
Vascular endothelial cells are barriers between blood and vascular wall. VEC damage is considered the starting point of As lesions.
Endothelial injury is often accompanied by different types of CD, such as autophagy, apoptosis, pyroptosis and necrosis. Vascular wall integrity is destroyed after pyroptosis, causing local lipid deposition, As formation and plaque instability, and even acute coronary occlusion and sudden death. 77 Caspase-1 is abundantly expressed in human As plaques; in fact, the caspase-1 content in vulnerable plaques and ruptured lesions in patients who died of acute coronary events is significantly increased. 78 Thus, pyroptosis is involved in As formation and plaque hardening. Recent studies support the role of mitochondrial adaptors, mitochondrial calcium fluxes and mitochondrial ROS (mtROS) generation in inflammasome activation. 83 Mitochondrial-derived mtROS is a major source of cellular ROS, and excessive mtROS is associated with
As progression in both human and mouse models. 64 Cadmium is a relatively common environmental metal pollutant that can cause As and hypertension. Cadmium activates NLRP3 inflammasome and downstream caspase-1 and IL-1β production by inducing mtROS, which mediates the pyroptosis of VECs and promotes the development of As. of target mRNAs to either facilitate their degradation or repress their translation. 85 In the present study, we find that miR-125a-5p
mediates oxLDL-induced pyroptosis in VECs by down-regulating tet methylcytosine dioxygenase 2 (TET2), increasing NF-κB activation, activating NLRP3 and caspase-1 p20, and ultimately causing pyroptosis of VECs. After TET2 down-regulation, abnormal DNA methylation occurs, and mitochondrial dysfunction subsequently induces ROS production, which activates the NLRP3 inflammasome, leading to the activation of caspase-1. Activated caspase-1 promotes GSDMD oligomerization, which triggers pore formation of the membrane, DNA fragmentation and release of mature IL-1β and IL-18 from cells, causing a sterile inflammatory response and further contributing to pyroptotic cell death and subsequently promoting As. The necrotic core is covered by a fibrous cap, and its "shoulder" region is infiltrated by activated T cells, macrophages and mast cells, which produce pro-inflammatory mediators that can render plaques unstable and can cause rupture of the fibrous cap, leading to vascular embolization and tissue infarction. 87 Although the death of macrophages in early As lesions is beneficial, the reduction in the number of these cells in the plaque can attenuate the inflammatory response and reduce the synthesis of matrix metalloproteinases. However, death of macrophages in advanced lesions promotes the formation of necrotic cores and the instability of As plaques. Macrophage death in As lesions causes the release of growth factors, cytokines, proteases and intracellular lipids to the inflammatory response; promotes plaque rupture and thrombosis; and causes acute cardiovascular events. 88, 89 Serum total cholesterol and low-density lipoprotein cholesterol (LDL-C) are risk factors for CHD, and oxLDL has a stronger effect to As. 90 OxLDL-induced macrophage pyroptosis plays an important role in As formation and plaque stability. OxLDL and cholesterol crystals in the plaque necrosis area can activate NLRP3 and caspase-1 to induce cell pyroptosis. This phenomenon causes the release of IL-18 and IL-1β in mouse macrophages, which exacerbates inflammation and As 91 ( Figure 4 ). Triglycerides are also another As risk factor, which can trigger pyroptosis and aggravate the disease. 92 IL-1β of the IL-1 family is an important pro-inflammatory cytokine that is mainly produced by activated monocytes/macrophages. 93 On the one hand, IL-1β activates monocytes, macrophages and neutrophils; on the other hand, it induces Th1 and Th17, thereby participating in the initiation of inflammatory and immune responses. 81 Depletion of IL-1β inhibits As and reduces the area of As plaque in Apo E −/− and IL-1 −/− mice by approximately 30% compared with the control group of Apo E −/− mice. 94 The lack of mitochondrial DNA (mtDNA) can also inhibit the formation and development of As. RHO0 cells (a type of cell line without mtDNA)
can resist apoptosis, and such mtDNA-depleted cells can resist oxLDL- NLRP3 inflammasome activation and IL-1β production, thereby inducing pyroptosis and promoting the formation and development of As.
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Sirtuin 1 (SIRT1), an NAD + -dependent deacetylase, is a key regulator in inflammatory response during CVDs. 99 Cluster of differentiation 40 (CD40), a molecule with pro-inflammatory properties, is a TNF receptor superfamily member, which participates in inflammatory events of CVDs. 100 Li et al 101 found that the level of SIRT1 is reduced in
ECs following LPS and ATP treatments. LPS and ATP trigger the activation of the NLRP3 inflammasome. Activation of SIRT1 inhibits NLRP3
inflammasome activation and subsequent pro-caspase-1 cleavage and IL-1β secretion by inhibiting the expression of CD40.
F I G U R E 4
Schematic of the primary molecular pathways leading to pyroptosis in monocytes/macrophages in CVDs. Internalization of oxidized low-density lipoprotein (oxLDL) by macrophages through CD36 receptor leads to intracellular gathering of cholesterol crystals in large phagolysosomal compartments. Cholesterol crystals can activate the NLRP3 inflammasome through lysosomal damage. oxLDL can also activate the NLRP3 inflammasome via the TLRs/NF-κB pathway. Activated NLRP3 inflammasome induces the release of mature IL-1β and IL-18 and further leads to inflammatory cell infiltration and pyroptosis inflammasome activation triggers sterile inflammation and pyroptosis. 110 Activation of inflammasomes can be inhibited by antioxidants, such as SIRT-1. Inhibition of the NLRP3 inflammasome or reduction of ROS production can significantly reduce myocardial IRI. 13, 111 In addition to CMs, CFs also play an important role in the maintenance of cardiac physiological functions. CFs are the most abundant cell type in the adult human heart, and they considerably affect the structure and function of the heart. 112 Øystein et al reported that the NLRP3 inflammasome is up-regulated in CFs and mediates myocardial IRI. 113 However, the role of CFs in CVDs remains to be further studied.
| Pyroptosis of vascular smooth muscle cells in atherosclerosis

| Diabetic cardiomyopathy
Diabetic cardiomyopathy (DCM) is one of the major complications of diabetes and is also the leading cause of death in diabetic patients. DCM is characterized by structural and functional impairments, including cardiomyocyte death, cardiac fibroblast activation, left ventricular dysfunction and metabolic disorders. Among them, the death of CMs and CFs is considered a fundamental change in DCM, which initiates cardiac remodelling and leads to left ventricular dysfunction. TXNIP is closely related to energy metabolism. TXNIP influences glucose metabolism by affecting hepatic glucose production and peripheral glucose uptake and regulating beta cell function. In addition, overexpression of TXNIP induces the apoptosis of pancreatic β-cells, reduces the sensitivity of peripheral tissues, such as skeletal muscle and fat, to insulin, and minimizes energy expenditure. 15, 115 The inflammatory response is involved in the development of DCM. Studies have shown that IL-1β is an essential pro-inflammatory cytokine in the development of DCM. The NLRP3 inflammasome also plays a crucial role in the inflammatory process in diabetic nephropathy and retinopathy.
116
In mammals, the Hu/ELAV RNA binding protein family consists of four highly conserved members, including HuR/HuA/Elavl1 and the neuronal-specific Hel-N1/HuB/Elavl2, HuC/Elavl3 and HuD/ Elavl4. All family members contain an RNA recognition motif with high affinity for U-and AU-rich sequences (AREs). 117 ELAVL1 is a member of the RNA binding protein family, which binds to ARE-and U-rich element (URE)-containing sequences and stabilizes mRNAs.
ELAVL1 plays a critical role in the progression of inflammation and HF. In HG state, ELAVL1 expression is increased in ventricular myocytes, which mediates TNF-α-induced myocardial pyroptosis.
Furthermore, ELAVL1 is the target gene of miR-9, and miR-9 expression is significantly down-regulated in high glucose (HG)-treated CMs and human diabetic hearts. ELAVL1 knockdown or miR-9 mimic transfection suppression of pyroptosis reduces caspase-1 and IL-1β expression. 118 Li et al 119 found the miR-30d expression is significantly increased in streptozotocin-induced diabetic rats and HG-treated CMs. 
| Pyroptosis of cardiac fibroblasts in DCM
NLRP3 inflammasome components have been identified in both
CMs and CFs, which are the two most abundant cell populations in the mammalian heart. The fibroblast can thus be a friend in normal function or a foe in pathophysiological conditions. Given their potential role in the regulation of global myocardial function, CFs represent an attractive therapeutic target in heart disease. 108 Cardiac fibrosis is one of the predominant pathological features of diabetic cardiomyopathy, and CFs play an important role in this process.
121
Long non-coding RNA is a type of RNA with a length of >200 nucleotides and non-coding protein. 122 In recent years, many reports have focused on the association of lncRNA with pyroptosis in CVDs, such as maternally expressed gene 3 (MEG3) 6 and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1). 17 The KCNQ1 opposite strand/anti-sense transcript 1 (Kcnq1ot1) is a lncRNA located in human chromosome 11p15. 
| Cardiac hypertrophy
The impairment of cardiac function caused by cardiac hypertrophy severely affects the quality of life of patients, but the underlying molecular mechanism remains unclear. In addition to hypertrophic cardiomyopathy, the most common cause of ventricular hypertrophy is long-term uncontrolled systolic hypertension and heart valve stenosis. 130 At from pyroptosis. Low doses of SA can also reduce the levels of endothelin-1 and IL-1β. In macrophages incubated with HG and oxLDL, they have similar effects on knockdown of MALAT1 and 1 μmol of SA.
17
Trimetazidine (TMZ) is an anti-ischaemic drug that significantly reduces intracellular acidosis and apoptosis, thereby protecting mitochondrial function and myocardium; TMZ is widely used to treat MI and other ischaemic heart diseases. 132 Sepsis is a life-threatening organ dysfunction syndrome caused by a host's dysfunctional response to infection and is one of the most common causes of death in hospitalized patients. 133 Cardiac dysfunction is a common complication of sepsis and an important cause of death. 134 Chen et al 135 reported that TMZ attenuates LPS-induced cardiomyocyte pyroptosis and cardiac dysfunction through promoting neutrophil recruitment to heart tissues by regulating chemokine CXC receptor 2 expression through the AMPK/Nrf2 pathway. This result suggests that TMZ is a potential therapeutic agent for septic cardiac dysfunction.
Melatonin (N-acetyl-5-methoxytryptamine), a neuroendocrine hormone mainly synthesized in the pineal, participates in sleepwake regulation and involved in many diseases, including CVDs. 136 Melatonin is a potent antioxidant with anti-atherogenic effects.
Latest research findings showed that administration of melatonin In the cardiovascular system, the pyroptosis of VECs causes the disintegration of blood vessel walls, which consequently promotes the occurrence of As and embolism induced by lipid deposition. 143 The pyroptosis of VSMCs results in unstable atherosclerotic plaques, acute coronary syndrome and stroke; monocytes/macrophages pyroptosis aggravates the inflammatory response and promotes the development and progression of various CVDs (such as As and MI). In the present review, in addition to the As, we mainly summarize the role of cardiomyocyte pyroptosis in CVDs. However, non-myocyte cell types in the myocardium, including CFs and mast cells, also play a crucial role in CVDs (eg, hypertensive heart disease and MI).
The heart is composed of 70% non-myocytes and 30% myocytes. 112 So far, few studies investigated the role of non-myocytes pyroptosis in CVDs. Thus, this research gap may be the focus of future studies. In the following years, we expect the development of new approaches on controlling the different forms of CD in clinical practice to provide new treatment strategies for patients with CVDs. 
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